SCHEMBL977514

SCHEMBL977514

CCOC(Cc1ccc(O)cc1)C(=O)OCC

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 9/20 0.54
ESR1 P03372 4/20 0.47
ESR2 Q92731 4/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
PPARG P37231 7/20 0.47
PPARD Q03181 3/20 0.47
PTGS2 P35354 2/20 0.45
BACE1 P56817 1/20 0.45
SLC7A5 Q01650 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL977513 1.00 PPARA (0.54) PPARAESR1ESR2CA12CA1
SCHEMBL6419166 1.00 PPARA (0.54) PPARAESR1ESR2CA12CA1
SCHEMBL5379694 0.89 ESR1 (0.45) PPARAESR1ESR2CA12CA1
SCHEMBL5379702 0.89 ESR1 (0.45) PPARAESR1ESR2CA12CA1
SCHEMBL14501971 0.89 PPARA (0.50) PPARAESR1ESR2CA12CA1
SCHEMBL3535227 0.89 ESR1 (0.58) PPARAESR1ESR2PPARGPPARD
SCHEMBL3535230 0.89 ESR1 (0.58) PPARAESR1ESR2PPARGPPARD
SCHEMBL2554435 0.88 PPARA (0.52) PPARAPPARGPPARD
SCHEMBL5360147 0.87 ESR1 (0.51) PPARAESR1ESR2CA12CA1
SCHEMBL3965096 0.87 PPARA (0.50) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1084101-B1 NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III ASTRAZENECA AB (SE) 2004-03-10 EP claimed
US-6660879-B2 Use of the compound in clinical conditions associated with insulin resistance. ASTRAZENECA AB (SE) 2003-12-09 US claimed
US-12201611-B2 Composition comprising high purity pyrrole derivative and method for preparation thereof ZYDUS LIFESCIENCES LIMITED (IN) 2025-01-21 US disclosed
CN-114080390-A Synthesis of coelenterazine 国际纸业公司 2022-02-22 CN disclosed
US-20220023262-A1 COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF ZYDUS LIFESCIENCES LIMITED (IN) 2022-01-27 US disclosed
EP-3830088-A1 SYNTHESIS OF COELENTERAZINE International Paper Company (US) 2021-06-09 EP disclosed
EP-3004053-B1 A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES CADILA HEALTHCARE LTD (IN) 2021-03-24 EP disclosed
EP-3004053-B1 A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES CADILA HEALTHCARE LTD (IN) 2021-03-24 EP disclosed
CN-112368286-A Synthesis of coelenterazine 国际纸业公司 2021-02-12 CN disclosed
EP-3024816-B1 PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES METABOLIC SOLUTIONS DEV CO LLC (US) 2020-06-03 EP disclosed
US-10435363-B2 Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities CADILA HEALTHCARE LIMITED (IN) 2019-10-08 US disclosed
WO-1999062870-A1 NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III ASTRAZENECA AB (SE) 1999-12-09 WO disclosed
WO-1999062872-A1 NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) ASTRAZENECA AB (SE) 1999-12-09 WO disclosed
WO-1999062871-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS ASTRAZENECA AB (SE) 1999-12-09 WO disclosed
WO-1999038850-A1 NOVEL ALKANOIC ACIDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-08-05 WO disclosed
CN-1219927-A Phenylalkylcarboxylic acid derivatives SANKYO CO (JP) 1999-06-16 CN disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed
WO-1999019313-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-22 WO disclosed
WO-1999016758-A1 NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-08 WO disclosed
WO-1999008501-A2 NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12201611-B2 Composition comprising high purity pyrrole derivative and method for preparation thereof DHPS, OGFOD1, OGDH PPARA 1843/4885ESR1 4476/4885ESR2 4019/4885
US-10435363-B2 Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities CYP51A1, LIPA, DHCR7 PPARA 418/4885ESR1 4181/4885ESR2 4697/4885
US-20220023262-A1 COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF DHPS, OGFOD1, OGDH PPARA 1843/4885ESR1 4476/4885ESR2 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.